SeaStar Medical Holding Corp

SeaStar Medical Holding Corp

SeaStar Medical Holding Corp is a publicly traded medical technology firm (NASDAQ: ICU) developing proprietary immunomodulatory therapies for critical care. The company's lead product candidate, the Selective Cytopheretic Device (SCD), is designed to treat hyper-inflammation in conditions such as acute kidney injury (AKI) and acute respiratory distress syndrome (ARDS). Founded by researchers and clinicians, the firm aims to address inflammatory conditions where few therapeutic options exist (per SEC filings, 2023). The firm's strategy centers on FDA-regulated medical devices that modulate the immune system. The SCD platform has received FDA Breakthrough Device designation and is currently in clinical trials. SeaStar does not operate as a traditional asset manager but as a biotech firm developing commercial therapies; its capital is deployed into clinical development and regulatory milestones. The company collaborates with institutions like the University of Minnesota and the Cleveland Clinic (per ClinicalTrials.gov, 2023). The company's team is led by CEO Eric Schlorff (appointed 2021) and includes a small group of R&D and medical affairs professionals. As a small-cap public company with limited financial disclosures, total team size is not publicly detailed. In December 2023, the firm reported positive interim data from its pediatric SCD trial in acute kidney injury (per company press release, December 2023). SeaStar does not operate like a family office; it is a clinical-stage medical device firm. The firm's structural differentiator is its focus on immune-modulating devices for critical care, a niche between biotech and medtech. Unlike most biotech firms targeting chronic conditions, SeaStar develops acute-care therapies. Its thin public profile and lack of venture capital backing distinguish it from well-funded peers, giving it a more exploratory posture as a microcap entity.